8 things to know about the newly approved weight-loss injection
THE TGA has approved the self-injectable weight loss drug liraglutide (Saxenda) for treating obesity.
Here are eight key things to know about the treatment.
- It is an analogue of human glucagon-like peptide-1 (GLP-1), a hormone that suppresses appetite.
- It has been approved as an adjunct to diet and exercise for patients with a BMI of 30 or above, and patients with a BMI of 27—29 with at least one weight-related comorbidity (such as pre-diabetes, type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea